Oppenheimer Issues Pessimistic Forecast for Corbus Pharmaceuticals (NASDAQ:CRBP) Stock Price

Posted by George Bondi on Aug 7th, 2026

Corbus Pharmaceuticals (NASDAQ:CRBP – Get Free Report) had its target price lowered by research analysts at Oppenheimer from $52.00 to $48.00 in a research report issued to clients and investors on Friday,Benzinga reports. The firm currently has an “outperform” rating on the biopharmaceutical company’s stock. Oppenheimer’s target price would indicate a potential upside of 383.09% from the company’s current price.

Other research analysts have also issued reports about the stock. Guggenheim reaffirmed a “buy” rating on shares of Corbus Pharmaceuticals in a research note on Tuesday, May 26th. Wall Street Zen upgraded Corbus Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday, June 20th. Jefferies Financial Group reduced their target price on Corbus Pharmaceuticals from $36.00 to $33.00 and set a “buy” rating for the company in a report on Tuesday, May 12th. Weiss Ratings restated a “sell (d-)” rating on shares of Corbus Pharmaceuticals in a research report on Friday, July 17th. Finally, HC Wainwright lowered their price target on Corbus Pharmaceuticals from $40.00 to $35.00 and set a “buy” rating on the stock in a research note on Friday. Eight analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. According to data from MarketBeat.com, Corbus Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $41.12.

Check Out Our Latest Research Report on CRBP

Corbus Pharmaceuticals Trading Up 2.0%

NASDAQ:CRBP traded up $0.20 during trading hours on Friday, reaching $9.94. 71,455 shares of the company were exchanged, compared to its average volume of 324,867. The stock’s 50-day moving average is $8.68 and its 200-day moving average is $9.04. The firm has a market cap of $184.11 million, a PE ratio of -1.71 and a beta of 2.59. Corbus Pharmaceuticals has a twelve month low of $7.12 and a twelve month high of $20.56.

Corbus Pharmaceuticals (NASDAQ:CRBP – Get Free Report) last announced its earnings results on Tuesday, August 11th. The biopharmaceutical company reported ($1.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.26) by ($0.55). As a group, research analysts anticipate that Corbus Pharmaceuticals will post -4.87 EPS for the current year.

Insider Transactions at Corbus Pharmaceuticals

In other Corbus Pharmaceuticals news, insider Nishant C. Saxena acquired 9,000 shares of the company’s stock in a transaction that occurred on Wednesday, June 3rd. The stock was bought at an average price of $7.58 per share, with a total value of $68,220.00. Following the purchase, the insider owned 75,300 shares in the company, valued at approximately $570,774. The trade was a 13.57% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director John Kenneth Jenkins sold 4,800 shares of the stock in a transaction dated Wednesday, June 10th. The shares were sold at an average price of $7.91, for a total transaction of $37,968.00. Following the completion of the sale, the director owned 3,833 shares of the company’s stock, valued at approximately $30,319.03. The trade was a 55.60% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 9,238 shares of company stock worth $73,073 over the last 90 days. 3.50% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Corbus Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Orbimed Advisors LLC boosted its stake in Corbus Pharmaceuticals by 8.8% during the first quarter. Orbimed Advisors LLC now owns 1,737,287 shares of the biopharmaceutical company’s stock worth $16,313,000 after buying an additional 140,000 shares during the last quarter. Prosight Management LP grew its holdings in Corbus Pharmaceuticals by 99.1% in the 4th quarter. Prosight Management LP now owns 683,872 shares of the biopharmaceutical company’s stock valued at $5,567,000 after buying an additional 340,472 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of Corbus Pharmaceuticals by 2.1% in the 3rd quarter. Vanguard Group Inc. now owns 612,030 shares of the biopharmaceutical company’s stock worth $7,742,000 after acquiring an additional 12,535 shares during the last quarter. Armistice Capital LLC raised its holdings in shares of Corbus Pharmaceuticals by 179.2% during the 4th quarter. Armistice Capital LLC now owns 536,000 shares of the biopharmaceutical company’s stock worth $4,363,000 after acquiring an additional 344,000 shares during the period. Finally, Renaissance Technologies LLC raised its holdings in shares of Corbus Pharmaceuticals by 230.5% during the 4th quarter. Renaissance Technologies LLC now owns 354,300 shares of the biopharmaceutical company’s stock worth $2,884,000 after acquiring an additional 247,100 shares during the period. Institutional investors and hedge funds own 64.64% of the company’s stock.

About Corbus Pharmaceuticals

(Get Free Report)

Corbus Pharmaceuticals Holdings, Inc is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of therapeutic candidates for rare, life-threatening inflammatory and fibrotic diseases. The company’s lead investigational therapy, lenabasum, is a synthetic, oral cannabinoid receptor type 2 (CB2) agonist designed to resolve chronic inflammation by harnessing the body’s innate resolution pathways. Corbus operates by advancing small-molecule compounds through preclinical and clinical studies to address unmet medical needs in autoimmune and inflammatory disorders.

Lenabasum is currently under evaluation in a Phase 3 clinical trial for diffuse cutaneous systemic sclerosis (dcSSc) and in a Phase 2 study for cystic fibrosis–related inflammation.